Efficacy and Safety of Treatment with Infliximab in Crohn's Disease: the Experience of Single Center in Korea.
- Author:
Kee Don CHOI
1
;
Ho Jun SONG
;
Joo Sung KIM
;
Hyun Chae JUNG
;
In Sung SONG
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. issong@snu.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Crohn's disease;
Infliximab
- MeSH:
Adult;
Antibodies, Monoclonal/adverse effects/*therapeutic use;
Crohn Disease/*drug therapy;
Female;
Gastrointestinal Agents/adverse effects/*therapeutic use;
Humans;
Immunosuppressive Agents/therapeutic use;
Male
- From:The Korean Journal of Gastroenterology
2005;46(1):48-55
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Infliximab has been shown to be effective and safe for treating refractory luminal and fistulizing Crohn's disease (CD). The aim of this study was to report the efficacy and adverse effect of infliximab therapy in patients with CD at our center. METHODS: Medical records of thirteen patients who were treated with infliximab for refractory luminal or fistulizing CD were reviewed. Clinical response was classified as complete response, partial response and nonresponse. RESULTS: Seven patients were treated for fistulizing CD, four patients for luminal CD, and two for both. The mean time of follow-up was 13.1 months (3.3-28.1 months). Clinical response was seen in 10/13 (77%); complete response 7/13 (54%), partial response 3/13 (23%), nonresponse 3/13 (23%). Mean time to response was 27.1 days (10-41 days). 4 of 10 responders (40%) maintained remission over 30 weeks. Those who started on immunosuppressive treatment more than 3 months before infliximab infusion achieved lower early recurrence rate (14%) compared with those less than 3 months (67%) (p=0.039). Steroid tapering was successful in 7/12 (58%). Five patients required surgical therapy; three nonresponders, one partial responder and one who recurred after initial complete response. Initial responders required less surgery than nonresponders (p=0.035). Acute infusion reactions were seen in 2/40 infusions (5%). One patient developed herpes zoster 20 weeks after infliximab infusion. During follow-up peried, no patient developed serious infection, tuberculosis or malignancy. CONCLUSIONS: Infliximab is effective and safe in clinical practice. Concurrent immunosuppressive use is associated with lower rate of early recurrence.
